Nitec Pharma AG, a Swiss drug company focused on chronic inflammation and pain-related diseases, has raised CHF 24 million (approx. $22m) in new VC funding. TVM Capital led the round, and was joined by Deutche Bank and return backers NGN Capital, Global Life Sciences Venture and Atlas Venture. www.nitecpharma.com
